GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » Debt-to-Revenue

China Isotope & Radiation (HKSE:01763) Debt-to-Revenue : 0.22 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

China Isotope & Radiation's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$238 Mil. China Isotope & Radiation's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,617 Mil. China Isotope & Radiation's annualized Revenue for the quarter that ended in Dec. 2023 was HK$8,519 Mil. China Isotope & Radiation's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.22.


China Isotope & Radiation Debt-to-Revenue Historical Data

The historical data trend for China Isotope & Radiation's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation Debt-to-Revenue Chart

China Isotope & Radiation Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only 0.22 0.18 0.17 0.15 0.26

China Isotope & Radiation Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.16 0.13 0.19 0.22

Competitive Comparison of China Isotope & Radiation's Debt-to-Revenue

For the Medical Devices subindustry, China Isotope & Radiation's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Isotope & Radiation's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where China Isotope & Radiation's Debt-to-Revenue falls into.



China Isotope & Radiation Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

China Isotope & Radiation's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(237.557 + 1616.969) / 7257.214
=0.26

China Isotope & Radiation's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(237.557 + 1616.969) / 8519.238
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


China Isotope & Radiation Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


China Isotope & Radiation (HKSE:01763) Business Description

Traded in Other Exchanges
N/A
Address
No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines